Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q2 2024 ▲▼ | Q3 2024 ▲▼ | Change ▲▼ | Q2 2024 ▲▼ | Q3 2024 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| Bristol-Myers Squibb Company(BMY) | 688,218 | 686,182 | -2,036 | $28.58M | $35.50M | 30.74% | +$6.92M |
| Biodesix, Inc.(BDSX) | 5,696,113 | 5,696,113 | 0 | $8.70M | $10.12M | 8.76% | +$1.42M |
| Acadia Pharmaceuticals Inc | 250,400 | 400,400 | +150,000 | $4.07M | $6.16M | 5.33% | +$2.09M |
| Elutia Inc.(ELUT) | 1,551,655 | 1,321,215 | -230,440 | $7.70M | $5.03M | 4.36% | -$2.66M |
| United Therapeutics Corporation(UTHR) | 10,000 | 10,000 | 0 | $3.19M | $3.58M | 3.10% | +$398.0K |
| Prothena Corp PlcSHS SHS | 203,574 | 209,574 | +6,000 | $4.20M | $3.51M | 3.04% | -$695.6K |
| Neurocrine Biosciences, Inc.(NBIX) | 42,240 | 30,240 | -12,000 | $5.82M | $3.48M | 3.02% | -$2.33M |
| Corcept Therapeutics Incorporated(CORT) | 74,000 | 74,000 | 0 | $2.40M | $3.42M | 2.97% | +$1.02M |
| Harrow, Inc.(HROW) | 150,000 | 72,910 | -77,090 | $3.13M | $3.28M | 2.84% | +$144.5K |
| Quidelortho Corp | 67,619 | 67,619 | 0 | $2.25M | $3.08M | 2.67% | +$837.1K |
| Foghorn Therapeutics Inc.(FHTX) | 320,930 | 320,930 | 0 | $1.85M | $2.99M | 2.59% | +$1.14M |
| Axogen, Inc.(AXGN) | 197,000 | 197,000 | 0 | $1.43M | $2.76M | 2.39% | +$1.34M |
| Phreesia, Inc.(PHR) | 114,700 | 114,700 | 0 | $2.43M | $2.61M | 2.26% | +$182.4K |
| Stoke Therapeutics, Inc.(STOK) | 210,000 | 210,000 | 0 | $2.84M | $2.58M | 2.23% | -$256.2K |
| Protagonist Therapeutics Inc | 48,000 | 48,000 | 0 | $1.66M | $2.16M | 1.87% | +$496.8K |
| Travere Therapeutics, Inc.(TVTX) | 122,000 | 148,000 | +26,000 | $1.00M | $2.07M | 1.79% | +$1.07M |
| Masimo Corp | 15,280 | 15,280 | 0 | $1.92M | $2.04M | 1.76% | +$112.9K |
| Ovintiv Inc.(OVV) | 74,200 | 52,200 | -22,000 | $3.48M | $2.00M | 1.73% | -$1.48M |
| DocGo Inc.(DCGO) | 460,000 | 515,000 | +55,000 | $1.42M | $1.71M | 1.48% | +$288.4K |
| Castle Biosciences, Inc.(CSTL) | 34,000 | 58,000 | +24,000 | $740.2K | $1.65M | 1.43% | +$914.0K |
| Alkermes plcSHS(ALKS) | 50,000 | 50,000 | 0 | $1.21M | $1.40M | 1.21% | +$194.5K |
| EQT Corporation(EQT) | 0 | 34,619 | +34,619 | $0 | $1.27M | 1.10% | +$1.27M |
| Alphatec Holdings, Inc.(ATEC) | 88,000 | 198,000 | +110,000 | $919.6K | $1.10M | 0.95% | +$181.3K |
| Kalvista Pharmaceuticals Inc | 46,000 | 82,000 | +36,000 | $541.9K | $949.6K | 0.82% | +$407.7K |
| Kiniksa Pharmaceuticals Ltd | 30,000 | 30,000 | 0 | $560.1K | $749.7K | 0.65% | +$189.6K |
| 10x Genomics, Inc.CL A(TXG) | 30,000 | 30,000 | 0 | $583.5K | $677.4K | 0.59% | +$93.9K |
| Halozyme Therapeutics, Inc.(HALO) | 10,000 | 10,000 | 0 | $523.6K | $572.4K | 0.50% | +$48.8K |
| Accelerate Diagnostics Inc | 325,239 | 325,239 | 0 | $380.5K | $556.2K | 0.48% | +$175.6K |
| Cytokinetics, Incorporated(CYTK) | 10,000 | 10,000 | 0 | $541.8K | $528.0K | 0.46% | -$13.8K |
| Inhibrx Biosciences, Inc.(INBX) | 12,110 | 32,110 | +20,000 | $170.6K | $502.8K | 0.44% | +$332.3K |
| Keros Therapeutics, Inc.(KROS) | 7,000 | 7,000 | 0 | $319.9K | $406.5K | 0.35% | +$86.6K |
| Apellis Pharmaceuticals Inc COM | 14,000 | 14,000 | 0 | $537.0K | $403.8K | 0.35% | -$133.3K |
| Treace Medical Concepts, Inc.(TMCI) | 0 | 68,350 | +68,350 | $0 | $396.4K | 0.34% | +$396.4K |
| Xenon Pharmaceuticals Inc.(XENE) | 10,000 | 10,000 | 0 | $389.9K | $393.7K | 0.34% | +$3.8K |
| Karyopharm Therapeutics Inc.(KPTI) | 469,832 | 469,832 | 0 | $407.6K | $390.0K | 0.34% | -$17.7K |
| Coherus Oncology, Inc.(CHRS) | 270,000 | 372,000 | +102,000 | $467.1K | $386.9K | 0.33% | -$80.2K |
| Arvinas, Inc.(ARVN) | 15,000 | 15,000 | 0 | $399.3K | $369.4K | 0.32% | -$29.9K |
| Progyny Inc | 22,000 | 22,000 | 0 | $629.4K | $368.7K | 0.32% | -$260.7K |
| Biohaven Pharmaceutical Holding Co Ltd | 7,365 | 7,365 | 0 | $255.6K | $368.0K | 0.32% | +$112.4K |
| Axsome Therapeutics, Inc.(AXSM) | 4,000 | 4,000 | 0 | $322.0K | $359.5K | 0.31% | +$37.5K |
| Cullinan Therapeutics, Inc.(CGEM) | 20,000 | 20,000 | 0 | $348.8K | $334.8K | 0.29% | -$14.0K |
| Wave Life Sciences, Inc.SHS(WVE) | 40,000 | 40,000 | 0 | $199.6K | $328.0K | 0.28% | +$128.4K |
| Springworks Therapeutics Inc | 10,000 | 10,000 | 0 | $376.7K | $320.4K | 0.28% | -$56.3K |
| NovoCure Limited(NVCR) | 20,000 | 20,000 | 0 | $342.6K | $312.6K | 0.27% | -$30.0K |
| Sarepta Therapeutics, Inc.(SRPT) | 2,500 | 2,500 | 0 | $395.0K | $312.2K | 0.27% | -$82.8K |
| BioCryst Pharmaceuticals, Inc.(BCRX) | 40,000 | 40,000 | 0 | $247.2K | $304.0K | 0.26% | +$56.8K |
| Amicus Therapeutics Inc COM | 28,000 | 28,000 | 0 | $277.8K | $299.0K | 0.26% | +$21.3K |
| Blueprint Medicines Corp | 0 | 2,700 | +2,700 | $0 | $249.8K | 0.22% | +$249.8K |
| Xencor, Inc.(XNCR) | 12,300 | 12,300 | 0 | $232.8K | $247.4K | 0.21% | +$14.5K |
| Gossamer Bio, Inc.(GOSS) | 138,176 | 138,176 | 0 | $124.5K | $136.3K | 0.12% | +$11.8K |
| Bluebird Bio Inc | 311,200 | 211,200 | -100,000 | $306.3K | $109.7K | 0.10% | -$196.6K |
| Alumis Inc | 0 | 10,000 | +10,000 | $0 | $106.8K | 0.09% | +$106.8K |
| Liquidia Corporation(LQDA) | 10,000 | 10,000 | 0 | $120.0K | $100.0K | 0.09% | -$20.0K |
| uniQure N.V.SHS(QURE) | 0 | 20,000 | +20,000 | $0 | $98.6K | 0.09% | +$98.6K |
| InflaRx N.V.(IFRX) | 50,000 | 50,000 | 0 | $87.0K | $76.5K | 0.07% | -$10.5K |
| 2seventy Bio Inc | 17,833 | 15,833 | -2,000 | $68.7K | $74.7K | 0.06% | +$6.1K |
| Ventyx Biosciences Inc | 28,800 | 28,800 | 0 | $66.5K | $62.8K | 0.05% | -$3.7K |
| Zentalis Pharmaceuticals, Inc.(ZNTL) | 16,000 | 16,000 | 0 | $65.4K | $58.9K | 0.05% | -$6.6K |
| Cabaletta Bio, Inc.(CABA) | 10,000 | 10,000 | 0 | $74.8K | $47.2K | 0.04% | -$27.6K |
| Outset Medical, Inc.(OM) | 10,000 | 10,000 | 0 | $38.5K | $6.8K | 0.01% | -$31.7K |
| CERo Therapeutics Holdings, Inc.CL A(CERO) | 12,972 | 12,972 | 0 | $3.9K | $1.2K | 0.00% | -$2.7K |
| Equitrans Midstream Corporatio | 133,050 | 0 | -133,050 | $1.73M | $0 | — | -$1.73M |
| Exxon Mobil Corp | 5,849 | 0 | -5,849 | $673.3K | $0 | — | -$673.3K |
| G1 Therapeutics Inc | 80,000 | 0 | -80,000 | $182.4K | $0 | — | -$182.4K |
| Silk Road Medical Inc | 158,094 | 0 | -158,094 | $4.27M | $0 | — | -$4.27M |